Teratogenicity of antiepileptic drugs: State of the art

Torbjörn Tomson, Dina Battino

Research output: Contribution to journalArticle

Abstract

Purpose of review: Information on the risks associated with antiepileptic drug (AED) use in pregnancy is necessary for a rational approach to the management of women of childbearing potential who have epilepsy. This reviews addresses recent reports on the risk for birth defects and impaired postnatal development attributable to prenatal exposure to AEDs. Recent findings: Some studies have indicated greater risk for birth defects as well as for lower verbal IQ in association with exposure to valproic acid, as compared with some other AEDs. The risk appears to be greater at doses above 800-1000 mg/day; lower doses may not carry higher risks than those associated with other AEDs. This observation is a cause of concern but more data are needed from prospective studies to assess the possible impact of confounding factors in order to clarify whether there is a causal relationship. Largescale pregnancy registries have been launched and are expected to provide more conclusive comparative data on the most frequently used AEDs in the near future. Summary: Although further studies are needed, it appears reasonable to use valproic acid with caution in women with epilepsy who are planning to become pregnant, and to consider prescribing other equally effective and safer AEDs if they are available. The importance of seizure control during pregnancy must not be neglected, and any attempt to change treatment should be done before conception. Drug withdrawal during pregnancy should be avoided, and patients should be made aware that definitive evidence on the relative safety of AEDs is lacking.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalCurrent Opinion in Neurology
Volume18
Issue number2
Publication statusPublished - Apr 2005

Fingerprint

Anticonvulsants
Pregnancy
Valproic Acid
Epilepsy
Registries
Seizures
Prospective Studies
Safety
Pharmaceutical Preparations
Therapeutics

Keywords

  • Antiepileptic drugs
  • Epilepsy
  • Pregnancy
  • Teratogenicity

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Teratogenicity of antiepileptic drugs : State of the art. / Tomson, Torbjörn; Battino, Dina.

In: Current Opinion in Neurology, Vol. 18, No. 2, 04.2005, p. 135-140.

Research output: Contribution to journalArticle

@article{ccb660946af342c08db2c87bdb9240cc,
title = "Teratogenicity of antiepileptic drugs: State of the art",
abstract = "Purpose of review: Information on the risks associated with antiepileptic drug (AED) use in pregnancy is necessary for a rational approach to the management of women of childbearing potential who have epilepsy. This reviews addresses recent reports on the risk for birth defects and impaired postnatal development attributable to prenatal exposure to AEDs. Recent findings: Some studies have indicated greater risk for birth defects as well as for lower verbal IQ in association with exposure to valproic acid, as compared with some other AEDs. The risk appears to be greater at doses above 800-1000 mg/day; lower doses may not carry higher risks than those associated with other AEDs. This observation is a cause of concern but more data are needed from prospective studies to assess the possible impact of confounding factors in order to clarify whether there is a causal relationship. Largescale pregnancy registries have been launched and are expected to provide more conclusive comparative data on the most frequently used AEDs in the near future. Summary: Although further studies are needed, it appears reasonable to use valproic acid with caution in women with epilepsy who are planning to become pregnant, and to consider prescribing other equally effective and safer AEDs if they are available. The importance of seizure control during pregnancy must not be neglected, and any attempt to change treatment should be done before conception. Drug withdrawal during pregnancy should be avoided, and patients should be made aware that definitive evidence on the relative safety of AEDs is lacking.",
keywords = "Antiepileptic drugs, Epilepsy, Pregnancy, Teratogenicity",
author = "Torbj{\"o}rn Tomson and Dina Battino",
year = "2005",
month = "4",
language = "English",
volume = "18",
pages = "135--140",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Teratogenicity of antiepileptic drugs

T2 - State of the art

AU - Tomson, Torbjörn

AU - Battino, Dina

PY - 2005/4

Y1 - 2005/4

N2 - Purpose of review: Information on the risks associated with antiepileptic drug (AED) use in pregnancy is necessary for a rational approach to the management of women of childbearing potential who have epilepsy. This reviews addresses recent reports on the risk for birth defects and impaired postnatal development attributable to prenatal exposure to AEDs. Recent findings: Some studies have indicated greater risk for birth defects as well as for lower verbal IQ in association with exposure to valproic acid, as compared with some other AEDs. The risk appears to be greater at doses above 800-1000 mg/day; lower doses may not carry higher risks than those associated with other AEDs. This observation is a cause of concern but more data are needed from prospective studies to assess the possible impact of confounding factors in order to clarify whether there is a causal relationship. Largescale pregnancy registries have been launched and are expected to provide more conclusive comparative data on the most frequently used AEDs in the near future. Summary: Although further studies are needed, it appears reasonable to use valproic acid with caution in women with epilepsy who are planning to become pregnant, and to consider prescribing other equally effective and safer AEDs if they are available. The importance of seizure control during pregnancy must not be neglected, and any attempt to change treatment should be done before conception. Drug withdrawal during pregnancy should be avoided, and patients should be made aware that definitive evidence on the relative safety of AEDs is lacking.

AB - Purpose of review: Information on the risks associated with antiepileptic drug (AED) use in pregnancy is necessary for a rational approach to the management of women of childbearing potential who have epilepsy. This reviews addresses recent reports on the risk for birth defects and impaired postnatal development attributable to prenatal exposure to AEDs. Recent findings: Some studies have indicated greater risk for birth defects as well as for lower verbal IQ in association with exposure to valproic acid, as compared with some other AEDs. The risk appears to be greater at doses above 800-1000 mg/day; lower doses may not carry higher risks than those associated with other AEDs. This observation is a cause of concern but more data are needed from prospective studies to assess the possible impact of confounding factors in order to clarify whether there is a causal relationship. Largescale pregnancy registries have been launched and are expected to provide more conclusive comparative data on the most frequently used AEDs in the near future. Summary: Although further studies are needed, it appears reasonable to use valproic acid with caution in women with epilepsy who are planning to become pregnant, and to consider prescribing other equally effective and safer AEDs if they are available. The importance of seizure control during pregnancy must not be neglected, and any attempt to change treatment should be done before conception. Drug withdrawal during pregnancy should be avoided, and patients should be made aware that definitive evidence on the relative safety of AEDs is lacking.

KW - Antiepileptic drugs

KW - Epilepsy

KW - Pregnancy

KW - Teratogenicity

UR - http://www.scopus.com/inward/record.url?scp=16444380586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16444380586&partnerID=8YFLogxK

M3 - Article

C2 - 15791143

AN - SCOPUS:16444380586

VL - 18

SP - 135

EP - 140

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 2

ER -